Ken Griffin Biotechnology

Citadel Advisors LLC

  • $550 Billion
  • Q2 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
NVO
Novo Nordisk A S
PUT
$268 Million
3.88M
Q2 2025
Reduced 76.93%
NVO
Novo Nordisk A S
CALL
$203 Million
2.94M
Q2 2025
Reduced 76.93%
REGN
Regeneron Pharmaceuticals, Inc.
CALL
$153 Million
291K
Q2 2025
Added 808.53%
VRTX
Vertex Pharmaceuticals Inc
CALL
$142 Million
319K
Q2 2025
Added 474.36%
MRNA
Moderna, Inc.
CALL
$130 Million
4.7M
Q2 2025
Added 4.23%
MRNA
Moderna, Inc.
PUT
$116 Million
4.2M
Q2 2025
Added 4.23%
REGN
Regeneron Pharmaceuticals, Inc.
PUT
$104 Million
198K
Q2 2025
Added 808.53%
VRTX
Vertex Pharmaceuticals Inc
PUT
$55.7 Million
125K
Q2 2025
Added 474.36%
CRSP
Crispr Therapeutics Ag
CALL
$47.5 Million
976K
Q2 2025
Reduced 92.67%
VKTX
Viking Therapeutics, Inc.
CALL
$29.1 Million
1.1M
Q2 2025
Reduced 47.13%
VKTX
Viking Therapeutics, Inc.
PUT
$21 Million
791K
Q2 2025
Reduced 47.13%
VRNA
Verona Pharma PLC
PUT
$20 Million
211K
Q2 2025
Added 306.33%
ALNY
Alnylam Pharmaceuticals, Inc.
CALL
$19.7 Million
60.3K
Q2 2025
Added 14092.61%
SMMT
Summit Therapeutics Inc.
CALL
$18.4 Million
863K
Q2 2025
Reduced 89.75%
BNTX
Bio N Tech Se
PUT
$18.2 Million
171K
Q2 2025
Reduced 98.77%
TGTX
Tg Therapeutics, Inc.
CALL
$17.9 Million
496K
Q2 2025
Added 61.71%
MDGL
Madrigal Pharmaceuticals, Inc.
PUT
$16.8 Million
55.4K
Q2 2025
Added 25785.02%
MDGL
Madrigal Pharmaceuticals, Inc.
CALL
$14.5 Million
47.8K
Q2 2025
Added 25785.02%
BNTX
Bio N Tech Se
CALL
$14.4 Million
136K
Q2 2025
Reduced 98.77%
TGTX
Tg Therapeutics, Inc.
PUT
$14.3 Million
398K
Q2 2025
Added 61.71%
CRSP
Crispr Therapeutics Ag
PUT
$14.3 Million
293K
Q2 2025
Reduced 92.67%
ALNY
Alnylam Pharmaceuticals, Inc.
PUT
$12.8 Million
39.3K
Q2 2025
Added 14092.61%
VRNA
Verona Pharma PLC
CALL
$11.4 Million
120K
Q2 2025
Added 306.33%
CYTK
Cytokinetics Inc
PUT
$11.3 Million
343K
Q2 2025
Added 12.87%
INSM
Insmed Inc
PUT
$11 Million
109K
Q2 2025
Added 309.08%
AXSM
Axsome Therapeutics, Inc.
PUT
$10.7 Million
103K
Q2 2025
Reduced 83.75%
BMRN
Biomarin Pharmaceutical Inc
CALL
$10.7 Million
194K
Q2 2025
Reduced 79.0%
AXSM
Axsome Therapeutics, Inc.
CALL
$10.2 Million
97.3K
Q2 2025
Reduced 83.75%
ARGX
Argenx Se
PUT
$9.87 Million
17.9K
Q2 2025
Added 56.9%
RPRX
Royalty Pharma PLC
CALL
$9.81 Million
272K
Q2 2025
Reduced 74.48%
ARGX
Argenx Se
CALL
$9.76 Million
17.7K
Q2 2025
Added 56.9%
INSM
Insmed Inc
CALL
$9.64 Million
95.8K
Q2 2025
Added 309.08%
BPMC
Blueprint Medicines Corp
PUT
$9.27 Million
72.3K
Q2 2025
Reduced 2.01%
BPMC
Blueprint Medicines Corp
CALL
$9.1 Million
71K
Q2 2025
Reduced 2.01%
RXRX
Recursion Pharmaceuticals, Inc.
CALL
$8.68 Million
1.72M
Q2 2025
Reduced 50.5%
SMMT
Summit Therapeutics Inc.
PUT
$8.38 Million
394K
Q2 2025
Reduced 89.75%
UTHR
United Therapeutics Corp
CALL
$7.84 Million
27.3K
Q2 2025
Added 289.71%
NVAX
Novavax Inc
PUT
$7.83 Million
1.24M
Q2 2025
Reduced 50.28%
BBIO
Bridge Bio Pharma, Inc.
PUT
$7.79 Million
180K
Q2 2025
Reduced 88.66%
BBIO
Bridge Bio Pharma, Inc.
CALL
$7.37 Million
171K
Q2 2025
Reduced 88.66%
CORT
Corcept Therapeutics Inc
CALL
$6.91 Million
94.2K
Q2 2025
Added 1478.05%
ACLX
Arcellx, Inc.
PUT
$6.64 Million
101K
Q2 2025
Reduced 72.68%
CORT
Corcept Therapeutics Inc
PUT
$6.45 Million
87.9K
Q2 2025
Added 1478.05%
SRPT
Sarepta Therapeutics, Inc.
PUT
$6.38 Million
373K
Q2 2025
Added 28.15%
AKRO
Akero Therapeutics, Inc.
PUT
$6.37 Million
119K
Q2 2025
Reduced 38.74%
SRPT
Sarepta Therapeutics, Inc.
CALL
$5.65 Million
330K
Q2 2025
Added 28.15%
BMRN
Biomarin Pharmaceutical Inc
PUT
$5.19 Million
94.4K
Q2 2025
Reduced 79.0%
RVMD
Revolution Medicines, Inc.
PUT
$4.87 Million
132K
Q2 2025
Added 1010.47%
JAZZ
Jazz Pharmaceuticals PLC
CALL
$4.55 Million
42.9K
Q2 2025
Reduced 10.73%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email